CONTEXT: Müllerian inhibiting substance (MIS) is produced in Sertoli cells of fetal testis and causes regression of müllerian ducts in male embryos. MIS also can induce the cell cycle arrest and apoptosis in müllerian duct-derived tumors in vivo and in vitro. OBJECTIVE: Our objective was to investigate the expression of MIS type II receptor (MISR II) and whether MIS can inhibit the proliferation and induce apoptosis in primary cultures of endometrial stromal cells (ESC) of endometriosis. DESIGN AND SETTINGS: In vitro experiments were performed in the university research laboratory. PARTICIPANTS: Tissue samples from 12 patients who had undergone evisceration for ovarian endometrial cysts were included in this study. INTERVENTIONS AND MAIN OUTCOME MEASURES: The expression of MISR II in ESC was investigated by immunohistochemistry. The cell viability and apoptosis in ESC treated with MIS was measured by methylthiazoletetrazolium assay and annexin V analysis. The expression of regulatory proteins in ESC treated with MIS was shown by Western blotting. RESULTS: ESC showed specific immunostaining for the MISR II. ESC treated with MIS exhibited 32% growth inhibition (P = 0.0001). The changes in cell cycle distribution after MIS exposure at 72 h demonstrated that S and G(2)M phases were decreased; G(0)G(1) and sub-G(0)G(1) phases were increased. ESC treated with MIS showed 13.72% annexin V-fluorescein isothiocyanate positivity. In the ESCs, which contain defective p16, MIS increased the expression of pocket proteins p107 and p130 and decreased E2F transcription factor 1. CONCLUSIONS: The results support a central role for MIS in endometriosis. Although the precise mechanism of MIS-mediated inhibition of ESC growth has not been fully defined, these data suggest that MIS has activity against ESC in vitro and may also be an effective targeted therapy for endometriosis.
CONTEXT: Müllerian inhibiting substance (MIS) is produced in Sertoli cells of fetal testis and causes regression of müllerian ducts in male embryos. MIS also can induce the cell cycle arrest and apoptosis in müllerian duct-derived tumors in vivo and in vitro. OBJECTIVE: Our objective was to investigate the expression of MIS type II receptor (MISR II) and whether MIS can inhibit the proliferation and induce apoptosis in primary cultures of endometrial stromal cells (ESC) of endometriosis. DESIGN AND SETTINGS: In vitro experiments were performed in the university research laboratory. PARTICIPANTS: Tissue samples from 12 patients who had undergone evisceration for ovarian endometrial cysts were included in this study. INTERVENTIONS AND MAIN OUTCOME MEASURES: The expression of MISR II in ESC was investigated by immunohistochemistry. The cell viability and apoptosis in ESC treated with MIS was measured by methylthiazoletetrazolium assay and annexin V analysis. The expression of regulatory proteins in ESC treated with MIS was shown by Western blotting. RESULTS: ESC showed specific immunostaining for the MISR II. ESC treated with MIS exhibited 32% growth inhibition (P = 0.0001). The changes in cell cycle distribution after MIS exposure at 72 h demonstrated that S and G(2)M phases were decreased; G(0)G(1) and sub-G(0)G(1) phases were increased. ESC treated with MIS showed 13.72% annexin V-fluorescein isothiocyanate positivity. In the ESCs, which contain defective p16, MIS increased the expression of pocket proteins p107 and p130 and decreased E2F transcription factor 1. CONCLUSIONS: The results support a central role for MIS in endometriosis. Although the precise mechanism of MIS-mediated inhibition of ESC growth has not been fully defined, these data suggest that MIS has activity against ESC in vitro and may also be an effective targeted therapy for endometriosis.
Authors: Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim Journal: Int J Oncol Date: 2011-05-13 Impact factor: 5.650
Authors: J K Schwarz; C H Bassing; I Kovesdi; M B Datto; M Blazing; S George; X F Wang; J R Nevins Journal: Proc Natl Acad Sci U S A Date: 1995-01-17 Impact factor: 11.205
Authors: H Jimbo; Y Hitomi; H Yoshikawa; T Yano; M Momoeda; A Sakamoto; O Tsutsumi; Y Taketani; H Esumi Journal: Am J Pathol Date: 1997-04 Impact factor: 4.307
Authors: Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe Journal: Proc Natl Acad Sci U S A Date: 2003-12-11 Impact factor: 11.205
Authors: Jae Yen Song; Keun Young Chen; Sue Yeon Kim; Mee Ran Kim; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; David T MacLaughlin; Jang Heub Kim Journal: Int J Oncol Date: 2009-06 Impact factor: 5.650
Authors: Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher Journal: J Assist Reprod Genet Date: 2017-06-22 Impact factor: 3.412
Authors: Yeon Soo Jung; Hee Jung Kim; Seok Kyo Seo; Young Sik Choi; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Hyuck Dong Han; Jae Wook Kim; Young Tae Kim Journal: Yonsei Med J Date: 2016-01 Impact factor: 2.759
Authors: Shin Young Kim; Hye Min Moon; Min Kyoung Lee; Youn Jee Chung; Jae Yen Song; Hyun Hee Cho; Mee Ran Kim; Jang Heub Kim Journal: Obstet Gynecol Sci Date: 2017-12-21
Authors: Marek Gowkielewicz; Aleksandra Lipka; Marta Majewska; Aleksandra Piotrowska; Marta Szadurska-Noga; Jacek J Nowakowski; Marta Wiszpolska; Piotr Dzięgiel; Tomasz Wasniewski; Mariusz Krzysztof Majewski; Marcin Jozwik Journal: Cells Date: 2020-10-17 Impact factor: 6.600